ERBB2 across 12 cancers
ERBB2 is on the target list of 12 of the briefings. A drug aimed at it carries an FDA label naming the disease in 6, and is approved for some indication in 12. In the reference cohorts of the 12 with a mutation landscape it is altered in at least 5% of patients in 8 and in under 2% in 2 (Lung cancer, Osteosarcoma) — a target there by expression, dependency or drug label, not by mutation.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Breast cancer | approved here Lapatinib, Margetuximab, Neratinib, Tucatinib | approved | 43 | 1 via HER2 | 2.81% mut · 11.5% amp n=1066 |
| Lung cancer | approved here Afatinib, Dacomitinib, Zenocutuzumab | approved | 43 | 3 via HER2 | 1.59% mut · 1.76% amp n=566 |
| Cholangiocarcinoma | approved here Zanidatamab, Zenocutuzumab | approved | 43 | 1 via HER2 | 4.08% mut n=417 |
| Colorectal cancer | approved here Tucatinib | approved | 43 | 1 via HER2 | 3.56% mut · 3.38% amp n=534 |
| Gallbladder cancer | approved here Zanidatamab | approved | 43 | 1 via HER2 | 7.3% mut · 10.3% amp n=233 |
| Esophageal cancer | approved here Zanidatamab | approved | 43 | 0 via HER2 | 6.04% mut · 15.38% amp n=182 |
| Gastric cancer | approved elsewhere | approved | 43 | 3 via HER2 | 5.28% mut · 13.24% amp n=436 |
| Bladder cancer | approved elsewhere | approved | 43 | 1 via HER2 | 12.2% mut · 5.39% amp n=410 |
| Osteosarcoma | approved elsewhere | approved | 43 | 1 via HER2 | 0.0% mut n=137 |
| Cervical cancer | approved elsewhere | approved | 43 | 0 via HER2 | 4.47% mut · 5.46% amp · 0.34% del n=291 |
| Endometrial cancer | approved elsewhere | approved | 43 | 0 via HER2 | 7.16% mut · 5.16% amp · 0.19% del n=517 |
| Small intestine cancer | approved elsewhere | approved | 43 | 0 via HER2 | 19.74% mut · 3.29% amp n=152 |
"Approved here" means a drug Open Targets records as aimed at ERBB2 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.